In recent years, there have been concerted efforts to generate clinically relevant pharmacological activators of AMPK and/or to repurpose/use existing drugs to combat various chronic metabolic disorders, including MAFLD and NASH/MASH (7, 9, 11, 12, 13, 14, 15). Here, PRKAA2 is linked to metabolic dysfunction-associated steatohepatitis.